Back HIV/AIDS HIV/AIDS Topics HIV Prevention

CROI 2017: STI Prophylaxis in PrEP Users Reduces Syphilis and Chlamydia, but Not Gonorrhea

Use of the antibiotic doxycycline as on-demand post-exposure prophylaxis by men who have sex with men taking part in the Ipergay HIV PrEP trial produced a 70% drop in chlamydia infections and a 73% drop in syphilis, but no reduction in gonorrhea, according to a late-breaking report at the 2017 Conference on Retroviruses and Opportunistic Infections (CROI) this week in Seattle.

alt

Read more:

Hope Overshadowed -- The National HIV PrEP Summit

The U.S. National HIV PrEP Summit, which took place in early December in San Francisco, was designed as an event of celebration and hope. Its structure, its speakers, even the way the plenary room was designed and the way the speakers dressed, all conveyed one message: we are all in this together, and pre-exposure prophylaxis (PrEP) really is the game-changer we have been looking for.

alt

Read more:

U.K.'s Largest Sexual Health Clinic Saw 40% Drop in New HIV Diagnoses in 2016

The clinic at 56 Dean Street in Soho, central London, the largest sexual health clinic in the U.K., saw an unprecedented 40% drop in new HIV diagnoses this year. Another clinic, the Mortimer Market Centre a mile away from Dean Street, has seen an even bigger 50% fall.

alt

Read more:

No New HIV Infections in Northern California Kaiser PrEP Program, but STI Rates Rising

No new HIV infections have been seen among nearly 1000 people who started Truvada for pre-exposure prophylaxis (PrEP) at Kaiser Permanente Northern California, according to a report in the December 15, 2016, Journal of Acquired Immune Deficiency Syndromes. The most recent analysis shows, however, that incidence of chlamydia and gonorrhea is high, suggesting that sexually transmitted infection (STI) testing may be needed quarterly rather than every 6 months.

alt

Read more:

First Large Study of Long-Acting Injectable for HIV Prevention Now Underway

The National Institutes of Health and industry collaborators last week launched a large-scale clinical trial to test long-acting injectable cabotegravir for HIV prevention. Study HPTN 083 will compare cabotegravir injections administered every 8 weeks versus once-daily oral tenofovir/emtricitabine (Truvada) pre-exposure prophylaxis (PrEP). Results are expected in 2021.

alt

Read more: